Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data...
-
-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on 80...
-
BRIDGEWATER, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
-
BRIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
-
BRIDGEWATER, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
-
First quarter 2020 total revenue of $48.6 million On track to achieve major 2020 milestones BRIDGEWATER, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT)...
-
BRIDGEWATER, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the...
-
Fourth quarter and full year 2019 total revenue of $59.9 million and $240.0 million, respectively New Drug Application accepted by FDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution,...
-
BRIDGEWATER, N.J., March 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that...
-
BRIDGEWATER, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...